during the rapidly evolving industry of oncology research, precise and economical mutation screening is important for producing targeted therapies. The KRAS companies Platform plays a pivotal function On this landscape by offering detailed answers for KRAS mutation profiling and Assessment. KRAS mutations, found in close to ninety five% of RAS-rela